|
1.
|
National Cancer Center: Cancer statistics
in Japan: 2011, http://ganjoho.jp/public/statistics/backnumber/2011_jp.html.
Accessed June 29, 2012.
|
|
2.
|
Tahara M, Ohtsu A, Hironaka S, Boku N,
Ishikura S, Miyata Y, Ogino T and Yoshida S: Clinical impact of
criteria for complete response (CR) of primary site to treatment of
esophageal cancer. Jpn J Clin Oncol. 35:316–323. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Pratt S, Shepard RL, Kandasamy RA,
Johnston PA, Perry W III and Dantzig AH: The multidrug resistance
protein 5 (ABCC5) confers resistance to 5-fluorouracil and
transports its monophosphorylated metabolites. Mol Cancer Ther.
4:855–863. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Kornmann M, Schwabe W, Sander S, Kron M,
Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H,
Häusler P, Ott K, Behnke D, Staib L, Beger HG and Link KH:
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA
expression levels: predictors for survival in colorectal cancer
patients receiving adjuvant 5-fluorouracil. Clin Cancer Res.
9:4116–4124. 2003.
|
|
5.
|
Ciaparrone M, Quirino M, Schinzari G,
Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G and Barone
C: Predictive role of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase expression in colorectal
cancer patients receiving adjuvant 5-fluorouracil. Oncology.
70:366–377. 2006. View Article : Google Scholar
|
|
6.
|
Larminat F and Bohr VA: Role of the human
ERCC-1 gene in gene-specific repair of cisplatin-induced DNA
damage. Nucleic Acids Res. 22:3005–3010. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Andersson BS, Sadeghi T, Siciliano MJ,
Legerski R and Murray D: Nucleotide excision repair genes as
determinants of cellular sensitivity to cyclophosphamide analogs.
Cancer Chemother Pharmacol. 38:406–416. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hsu DS, Lan HY, Huang CH, Tai SK, Chang
SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY and Yang MH:
Regulation of excision repair cross-complementation group 1 by
Snail contributes to cisplatin resistance in head and neck cancer.
Clin Cancer Res. 16:4561–4571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Shimada Y, Imamura M, Wagata T, Yamaguchi
N and Tobe T: Characterization of 21 newly established esophageal
cancer cell lines. Cancer. 69:277–284. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kitada N, Takara K, Minegaki T, Itoh C,
Tsujimoto M, Sakaeda T and Yokoyama T: Factors affecting
sensitivity to antitumor platinum derivatives of human colorectal
tumor cell lines. Cancer Chemother Pharmacol. 62:577–584. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kimura N, Masuda S, Tanihara Y, Ueo H,
Okuda M, Katsura T and Inui K: Metformin is a superior substrate
for renal organic cation transporter OCT2 rather than hepatic OCT1.
Drug Metab Pharmacokinet. 20:379–386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Filipski KK, Loos WJ, Verweij J and
Sparreboom A: Interaction of Cisplatin with the human organic
cation transporter 2. Clin Cancer Res. 14:3875–3880. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Karasawa H, Miura K, Fujibuchi W, Ishida
K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H,
Takami K, Yamamura A, Shibata C and Sasaki I: Down-regulation of
cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in
human colon cancer cells. Cancer Sci. 100:903–913. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Takara K, Obata Y, Yoshikawa E, Kitada N,
Sakaeda T, Ohnishi N and Yokoyama T: Molecular changes to HeLa
cells on continuous exposure to cisplatin or paclitaxel. Cancer
Chemother Pharmacol. 58:785–793. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Takenaka T, Yoshino I, Kouso H, Ohba T,
Yohena T, Osoegawa A, Shoji F and Maehara Y: Combined evaluation of
Rad51 and ERCC1 expressions for sensitivity to platinum agents in
non-small cell lung cancer. Int J Cancer. 121:895–900. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Noma B, Sasaki T, Fujimoto Y, Serikawa M,
Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T and Chayama K:
Expression of multidrug resistance-associated protein 2 is involved
in chemotherapy resistance in human pancreatic cancer. Int J Oncol.
33:1187–1194. 2008.PubMed/NCBI
|
|
17.
|
Lan L, Hayashi T, Rabeya RM, Nakajima S,
Kanno S, Takao M, Matsunaga T, Yoshino M, Ichikawa M, Riele H,
Tsuchiya S, Tanaka K and Yasui A: Functional and physical
interactions between ERCC1 and MSH2 complexes for resistance to
cisdiamminedichloroplatinum(II) in mammalian cells. DNA Repair
(Amst). 3:135–143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Takizawa M, Kawakami K, Obata T, Matsumoto
I, Ohta Y, Oda M, Sasaki T and Watanabe G: In vitro sensitivity to
platinum-derived drugs is associated with expression of thymidylate
synthase and dihydropyrimidine dehydrogenase in human lung cancer.
Oncol Rep. 15:1533–1539. 2006.
|
|
19.
|
Pettersen HS, Visnes T, Vågbø CB, Svaasand
EK, Doseth B, Slupphaug G, Kavli B and Krokan HE: UNG-initiated
base excision repair is the major repair route for 5-fluorouracil
in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA
incorporation. Nucleic Acids Res. 39:8430–8444. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Li Y, Mizutani Y, Shiraishi T, Nakamura T,
Mikami K, Takaha N, Okihara K, Kawauchi A, Sakai T and Miki T: The
significance of the expression of dihydropyrimidine dehydrogenase
in prostate cancer. BJU Int. 99:663–668. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ando T, Ishiguro H, Kuwabara Y, Kimura M,
Mitsui A, Sugito N, Mori R, Ogawa R, Katada T and Fujii Y:
Relationship between expression of 5-fluorouracil metabolic enzymes
and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.
Dis Esophagus. 21:15–20. 2008.PubMed/NCBI
|
|
22.
|
Pedersen JM, Matsson P, Bergström CA,
Norinder U, Hoogstraate J and Artursson P: Prediction and
identification of drug interactions with the human ATP-binding
cassette transporter multidrug-resistance associated protein 2
(MRP2; ABCC2). J Med Chem. 51:3275–3287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Reidling JC, Subramanian VS, Dahhan T,
Sadat M and Said HM: Mechanisms and regulation of vitamin C uptake:
studies of the hSVCT systems in human liver epithelial cells. Am J
Physiol Gastrointest Liver Physiol. 295:1217–1227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Nishimura M, Koeda A, Morikawa H, Satoh T,
Narimatsu S and Naito S: Comparison of inducibility of multidrug
resistance (MDR)1, multidrug resistance-associated protein (MRP)1,
and MRP2 mRNAs by prototypical microsomal enzyme inducers in
primary cultures of human and cynomolgus monkey hepatocytes. Biol
Pharm Bull. 31:2068–2072. 2008. View Article : Google Scholar
|
|
25.
|
Maubon N, Le Vee M, Fossati L, Audry M, Le
Ferrec E, Bolze S and Fardel O: Analysis of drug transporter
expression in human intestinal Caco-2 cells by real-time PCR.
Fundam Clin Pharmacol. 21:659–663. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Dauchy S, Miller F, Couraud PO, Weaver RJ,
Weksler B, Romero IA, Scherrmann JM, De Waziers I and Declèves X:
Expression and transcriptional regulation of ABC transporters and
cytochromes P450 in hCMEC/D3 human cerebral micro-vascular
endothelial cells. Biochem Pharmacol. 77:897–909. 2009. View Article : Google Scholar
|
|
27.
|
Shimizu J, Horio Y, Osada H, Hida T,
Hasegawa Y, Shimokata K, Takahashi T, Sekido Y and Yatabe Y: mRNA
expression of RRM1, ERCC1 and ERCC2 is not associated with
chemosensitivity to cisplatin, carboplatin and gemcitabine in human
lung cancer cell lines. Respirology. 13:510–517. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Sliwinski T, Krupa R, Majsterek I, Rykala
J, Kolacinska A, Morawiec Z, Drzewoski J, Zadrozny M and Blasiak J:
Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast
Cancer Res Treat. 94:105–109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Amirrad M, Al-Mulla F, Varadharaj G, John
B, Saji T and Anim JT: BRCA1 gene expression in breast cancer in
Kuwait: correlation with prognostic parameters. Med Princ Pract.
14:67–72. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Müller A, Zielinski D, Friedrichs N,
Oberschmid B, Merkelbach-Bruse S, Schackert HK, Linnebacher M, von
Knebel Doeberitz M, Büttner R and Rüschoff J: Reduced mRNA
expression in paraffin-embedded tissue identifies MLH1-and
MSH2-deficient colorectal tumours and potential mutation carriers.
Virchows Arch. 453:9–16. 2008.PubMed/NCBI
|
|
31.
|
Veeriah S, Kautenburger T, Habermann N,
Sauer J, Dietrich H, Will F and Pool-Zobel BL: Apple flavonoids
inhibit growth of HT29 human colon cancer cells and modulate
expression of genes involved in the biotransformation of
xenobiotics. Mol Carcinog. 45:164–174. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Uthus EO, Reeves PG and Saari JT: Copper
deficiency decreases plasma homocysteine in rats. J Nutr.
137:1370–1374. 2007.PubMed/NCBI
|
|
33.
|
Hoang YD, Avakian AP and Luderer U:
Minimal ovarian upregulation of glutamate cysteine ligase
expression in response to suppression of glutathione by buthionine
sulfoximine. Reprod Toxicol. 21:186–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Gustavsson B, Kaiser C, Carlsson G,
Wettergren Y, Odin E, Lindskog EB, Niyikiza C and Ma D: Molecular
determinants of efficacy for 5-FU-based treatments in advanced
colorectal cancer: mRNA expression for 18 chemotherapy-related
genes. Int J Cancer. 124:1220–1226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Yoshinare K, Kubota T, Watanabe M, Wada N,
Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M:
Gene expression in colorectal cancer and in vitro chemosensitivity
to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci.
94:633–638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Matsubara J, Nishina T, Yamada Y, Moriwaki
T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada
Y, Okayama Y, Oka T and Shirao K: Impacts of excision repair
cross-complementing gene 1 (ERCC1), dihydropyrimidine
dehydrogenase, and epidermal growth factor receptor on the outcomes
of patients with advanced gastric cancer. Br J Cancer. 98:832–839.
2008. View Article : Google Scholar
|
